TrialNature communications2026

Neoadjuvant PD1 plus CTLA-4 immune checkpoint blockade in surgically resectable recurrent glioblastoma: a randomized surgical window-of-opportunity trial.

Lu Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.